Dyslipidemia is a major risk factor for peripheral arterial disease (PAD). Management of dyslipidemia is based on the National Cholesterol Educational Panel’s (NCEP) guidelines, initially published in 1988. These guidelines are based on a large body of evidence that demonstrates…
There are few contemporary studies concerning the cardiovascular (CV) risks caused by hypertension or the benefits of its treatment during the perioperative period. Conversely, numerous trials have evaluated the potential benefits of specific antihypertensive medications, in particular beta-blockers. The 2007…
High blood pressure (BP) is the leading risk factor for global morbidity and mortality. Clinical trials in hypertension have largely focused on the efficacy of oral medications to lower BP and reduce cardiovascular events. However, a variety of other nonpharmacologic…
Hypertension is a polygenetic disorder provoked by remediable (e.g., sodium intake) as well as unmodifiable factors (e.g., aging). It accounts for up to half of cardiovascular events and is the leading risk factor for morbidity and mortality worldwide. To combat…